<div id="readability-page-1"><p>Inspire Investing LLC bought a new position in  CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund bought 522,482 shares of the biotechnology company's stock, valued at approximately $1,667,000. Inspire Investing LLC owned approximately 0.32% of CytomX Therapeutics at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>CytomX Therapeutics</strong> alerts:</span></p></div><p>Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Orbimed Advisors LLC bought a new position in  CytomX Therapeutics in the 2nd quarter worth about $19,208,000.  Commodore Capital LP bought a new stake in  CytomX Therapeutics during the 2nd quarter valued at about $17,462,000.  Perceptive Advisors LLC purchased a new position in  CytomX Therapeutics in the second quarter worth about $15,876,000.  Vivo Capital LLC bought a new position in shares of  CytomX Therapeutics in the second quarter worth approximately $13,096,000.  Finally, Franklin Resources Inc. purchased a new stake in shares of  CytomX Therapeutics during the second quarter valued at approximately $13,096,000. 67.77% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts have commented on the company. HC Wainwright increased their target price on CytomX Therapeutics from $5.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 11th. Barclays upped their price target on CytomX Therapeutics from $3.50 to $6.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, October 21st. Wedbush  reiterated an &#34;outperform&#34; rating and issued a $6.00 price objective on shares of CytomX Therapeutics in a report on Friday, November 7th. Wall Street Zen lowered CytomX Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a report on Monday, September 22nd. They set an &#34;overweight&#34; rating and a $6.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and one  has assigned  a Hold rating to the stock. According to MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p><p><b>View Our Latest Analysis on CTMX</b></p><h2>CytomX Therapeutics Stock Up 5.6%</h2><p>NASDAQ CTMX opened at $4.44 on Friday. The company has a 50-day moving average price of $3.89 and a 200-day moving average price of $2.93. CytomX Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $4.62. The firm has a market capitalization of $751.42 million, a P/E ratio of 11.09 and a beta of 2.37. </p><p>CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). CytomX Therapeutics had a net margin of 24.66% and a return on equity of 44.49%. The business had revenue of $5.96 million for the quarter, compared to the consensus estimate of $11.50 million.  As a group, equities research analysts anticipate that  CytomX Therapeutics, Inc. will post -0.05 EPS for the current year. </p><h2>About CytomX Therapeutics</h2> (Free Report)<p>CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.  </p><p>At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than CytomX Therapeutics</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li></ul><p><strong>Want to see what other hedge funds are holding CTMX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RNWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RNWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CytomX Therapeutics Right Now?</h2><p>Before you consider CytomX Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.</p><p>While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CTMX

<p>Inspire Investing LLC acquired 522,482 shares of CytomX Therapeutics, valued at $1,667,000, during the 3rd quarter. The acquisition was reported in a Form 13F filing with the SEC. Analysts have set new price targets for CytomX, with HC Wainwright raising its target to $10.00 and Barclays to $6.00. The stock has a "Moderate Buy" rating with a consensus target price of $6.67. CytomX's stock price increased by 5.6%, opening at $4.44 on Friday.</p>

Inspire Investing LLC Acquires Shares of 522,482 CytomX Therapeutics, Inc. $CTMX